Internal Application No
PCT/GB2004/005421

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07C405/00 C07C59/90 A61K31/5575 A61K31/192 A61P37/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) CO7C A61K A61P IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, CHEM ABS Data, BEILSTEIN Data, WPI Data, BIOSIS, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Category o Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X SZCZEPAN JOZEFOWSKI ET AL.: "Exogenous 11,15but not endogenous prostanoids regulate cytokine secretion from murine bone marrow dendritic cells: EP2, DP, and IP but not EP1, EP3, and FP prostanoid receptors are involved" INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 3, 1 June 2003 (2003-06-01), pages 865-878, XP002325093 abstract paragraph '03.3! -/--Χ Further documents are listed in the continuation of box C. Patent family members are listed in annex. Special categories of cited documents: "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled document referring to an oral disclosure, use, exhibition or other means in the art. "P" document published prior to the international filing date but later than the priority date claimed *&* document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 19 April 2005 02/05/2005 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016 Goetz, G

Internal Application No
PCT/GB2004/005421

ation) DOCUMENTS CONSIDERED TO BE RELEVANT	FC1/GB2004/005421
Citation of document, with Indication, where appropriate, of the relevant passages	Relevant to claim No.
NIALS A T ET AL: "AH13205, A SELECTIVE	11,13,
PROSTANOID EP2-RECEPTOR AGONIST" CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 11, no. 2, 1993, pages 165-179, XP009004866 ISSN: 0897-5957 the whole document	15,17
VANCHERI C ET AL: "The lung as a privileged site for the beneficial actions of PGE2" TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 25, no. 1, January 2004 (2004-01), pages 40-46, XP004481206 ISSN: 1471-4906	11,13, 15,17
KANDA N ET AL: "Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 114, no. 6, December 2004 (2004-12), pages 1403-1409, XP004666387 ISSN: 0091-6749 the whole document	12,16
HILLOCK C J ET AL: "INHIBITORY PROSTANOID EP RECEPTORS IN HUMAN NON-PREGNANT MYOMETRIUM" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 378, no. 1, 28 July 1999 (1999-07-28), pages 99-108, XP001124311 ISSN: 0014-2999 cited in the application the whole document	
WO 03/037433 A (ALLERGAN, INC) 8 May 2003 (2003-05-08) cited in the application the whole document	1
	NIALS A T ET AL: "AH13205, A SELECTIVE PROSTANOID EP2—RECEPTOR AGONIST" CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, vol. 11, no. 2, 1993, pages 165—179, XP009004866 ISSN: 0897—5957 the whole document VANCHERI C ET AL: "The lung as a privileged site for the beneficial actions of PGE2" TRENDS IN IMMUNOLOGY, ELSEVIER, CAMBRIDGE, GB, vol. 25, no. 1, January 2004 (2004—01), pages 40—46, XP004481206 ISSN: 1471—4906 the whole document KANDA N ET AL: "Prostaglandin E2 suppresses CCL27 production through EP2 and EP3 receptors in human keratinocytes" JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY — YEARLY BOOK, INC, US, vol. 114, no. 6, December 2004 (2004—12), pages 1403—1409, XP004666387 ISSN: 0091—6749 the whole document HILLOCK C J ET AL: "INHIBITORY PROSTANOID EP RECEPTORS IN HUMAN NON—PREGNANT MYOMETRIUM" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 378, no. 1, 28 July 1999 (1999—07—28), pages 99—108, XP001124311 ISSN: 0014—2999 cited in the application the whole document WO 03/037433 A (ALLERGAN, INC) 8 May 2003 (2003—05—08) cited in the application

International application No. PCT/GB2004/005421

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)		
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:		
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:		
Although claims 9, 10, 15 - 18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.		
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:		
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
This International Searching Authority found multiple inventions in this international application, as follows:		
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.		
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.		
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:		
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:		
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.		

Information on patent family members

Internation No
PCT/GB2004/005421